Liposomal Anthracyclin in the Treatment of Elderly ALL
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00600977|
Recruitment Status : Completed
First Posted : January 25, 2008
Last Update Posted : June 26, 2008
|Condition or disease||Intervention/treatment||Phase|
|Acute Lymphoblastic Leukemia||Drug: Doxorubicine Drug: Doxorubicine pegylated||Phase 2|
Patients aged 55 years or over will be assessed for response to steroids from day -7 to day 0 During steroid therapy, Ph status will be determinated : patients with Ph+ ve ALL will be treated according to the another French Protocol while patients with Ph-ve ALL will be included in the "caelyx" protocol and randomly allocated to induction with VAD or with vadox-li-Peg (caelyx).
A second course of induction therapy with VAD+ cyclophosphamide of Vadox-li-peg+ cyclophosphamide(according to the initial randomization arm) will then be given to all patients.
Consolidation therapy included 2 courses of vad or of vadox-li-Peg , according to the initial random allocation, followed by two courses of cytarabine,cyclophosphamide and thioguanine.
During induction and consolidation therapy, doxorubicin and liposomal pegylated doxorubicin pharmacokinetics will be assessed in all patients.
Treatment of occult CNS invasion includes skull radiotherapy and 6 intrathecal injections(steroÏds+methotrexate) A two years maintenance course with 6 mercaptopurine and methotrexate will then be offered to all patients.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicentric Phase II-III Randomized Study Safety of Intraveinous Liposomal Pegylated Doxorubicin Versus Continuous Infusion of Doxorubicin During Induction Treatment of Acute Lymphoblastic Leukemia in Patients|
|Study Start Date :||March 2002|
|Actual Study Completion Date :||October 2006|
Active Comparator: doxorubicine
9mg/m² J1 J4 2 COURSES
Experimental: Doxorubicine pegylated
Doxorubicine pegylated 40 MG/M² J1
Drug: Doxorubicine pegylated
40 MG/M² J1 2 courses
- Number of patients alive by day 113 ( last injection of anthracycline ) and having received a full course of induction/consolidation therapy [ Time Frame: 113 days ]
- Hematological and cutaneous adverse evnts of both types of chemotherapy [ Time Frame: 113 days ]
- Resistance to chemotherapy [ Time Frame: 113 days ]
- Complete response rates [ Time Frame: 113 days ]
- Disease free and overall survival [ Time Frame: 4 months ]
- Economical study [ Time Frame: 113 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00600977
|Regional university hospital|
|Angers, France, 49000|
|Principal Investigator:||Mathilde HUNAULT BERGER, RN||French Innovative Leukemia Organisation|